SEC Filing | Kymera Therapeutics, Inc.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

View:

Download DOC

Download PDF

Download XLS

Download XBRL

kymr-10q_20210331.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________________ to ___________________

Commission File Number: 001-39460

KYMERA THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	81-2992166
(State or other jurisdiction of incorporation or organization	(I.R.S. Employer Identification No.)

200 Arsenal Yards Blvd., Suite 230 Watertown, Massachusetts	02472
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (857) 285-5300

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

KYMR

The Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As April 30, 2021, the registrant had 45,030,094 shares of common stock, $0.0001 par value per share, outstanding.

Summary of the Material and Other Risks Associated with Our Business

•

We are a biopharmaceutical company with a limited operating history and have not generated any revenue to date from drug sales, and may never become profitable.

•

We have incurred significant operating losses in recent periods and anticipate that we will incur continued losses for the foreseeable future.

•

We will need to raise substantial additional funding. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, scale back or discontinue some of our product candidate development programs or future commercialization efforts.

•

We are very early in our development efforts and our IRAK4, IRAKIMiD, and STAT3 programs are still in preclinical or early clinical development. If we are unable to advance them into and through the clinic for safety or efficacy reasons or commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.

•

Our approach to the discovery and development of product candidates based on our Pegasus platform is novel and unproven, which makes it difficult to predict the time, cost of development, and likelihood of successfully developing any products.

•

Business interruptions resulting from the coronavirus disease (COVID-19) outbreak or similar public health crises could cause a disruption of the development of our product candidates and adversely impact our business.

•

We may not be successful in our efforts to identify or discover additional product candidates or we may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.

•

If we experience delays or difficulties in the initiation or enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.

•

Our current or future product candidates may cause adverse or other undesirable side effects that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.

•

Even if we receive regulatory approval for any of our current or future product candidates, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense.

•

We rely, and expect to continue to rely, on third parties to conduct our ongoing and planned clinical trials for our current and future product candidates. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for or commercialize our current and potential future product candidates and our business could be substantially harmed.

•

If we are unable to obtain and maintain patent and other intellectual property protection for our technology and product candidates or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and drugs may be impaired.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “expects”, “intends”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, “continue” or the negative of these terms or other comparable terminology. These statements are not guarantees of future results or performance and involve substantial risks and uncertainties. Forward-looking statements in this Quarterly Report include, but are not limited to, express or implied statements about:

•

the initiation, timing, progress, results, and cost of our research and development programs, and our current and future preclinical and future clinical studies, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs;

•

our ability to continue to construct Pegasus, our drug discovery platform, and to enable a rational and effective drug discovery and development engine;

•

the timing and the success of preclinical and clinical studies under our IRAK4, IRAKIMiD, and STAT3 programs;

•

our plans to submit investigational new drug applications to the FDA for current and future product candidates;

•

the subsequent initiation of planned clinical trials;

•

our ability to identify research priorities and apply a risk-mitigated strategy to efficiently discover and develop product candidates, including by applying learnings from one program to other programs and from one modality to our other modalities;

•

our potential ability to manufacture our drug substances, delivery vehicles, and product candidates for preclinical use, for clinical trials and on a larger scale for commercial use, if approved;

•

the ability and willingness of our third-party strategic collaborators to continue research and development activities relating to our development candidates and product candidates;

•

our ability to obtain funding for our operations necessary to complete further development and commercialization of our product candidates;

•

our ability to obtain and maintain regulatory approval of our product candidates;

•

our ability to commercialize our products, if approved;

•

the pricing and reimbursement of our product candidates, if approved;

•

the implementation of our business model, and strategic plans for our business, product candidates, and technology;

•

the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;

•

estimates of our future expenses, revenues, capital requirements, and our needs for additional financing;

•

the potential benefits of strategic collaboration agreements, our ability to enter into strategic collaborations or arrangements, and our ability to attract collaborators with development, regulatory and commercialization expertise;

•

future agreements with third parties in connection with the commercialization of product candidates and any other approved product;

•

the size and growth potential of the markets for our product candidates, and our ability to serve those markets;

•

our financial performance;

•

the rate and degree of market acceptance of our product candidates;

•

regulatory developments in the United States and foreign countries;

•

our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;

•

our ability to produce our products or product candidates with advantages in turnaround times or manufacturing cost;

•

the success of competing therapies that are or may become available;

•

our ability to attract and retain key scientific or management personnel;

•

the impact of laws and regulations;

•

developments relating to our competitors and our industry;

•

the effect of the COVID-19 pandemic, including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to our preclinical studies and future clinical trials;

•

our expectations regarding the time during which we will continue to be an emerging growth company or smaller reporting company as defined in federal securities regulations; and

•

other risks and uncertainties, including those listed under the caption “Risk Factors.”

Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events and with respect to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those described under Part II, Item 1A, “Risk Factors” and elsewhere in this Quarterly Report. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

All of our forward-looking statements are as of the date of this Quarterly Report only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of or any material adverse change in one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the Securities and Exchange Commission, or the SEC, could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report that modify or impact any of the forward-looking statements contained in this Quarterly Report will be deemed to modify or supersede such statements in this Quarterly Report.

We may from time to time provide estimates, projections and other information concerning our industry, the general business environment, and the markets for certain diseases, including estimates regarding the potential size of those markets and the estimated incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events, circumstances or numbers, including actual disease prevalence rates and market size, may differ materially from the information reflected in this Quarterly Report. Unless otherwise expressly stated, we obtained this industry, business information, market data, prevalence information and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources, in some cases applying our own assumptions and analysis that may, in the future, prove not to have been accurate.

iii

Table of Contents

		Page
PART I.	FINANCIAL INFORMATION	1
Item 1.	Financial Statements (Unaudited)	1
	Condensed Consolidated Balance Sheets	1
	Condensed Consolidated Statements of Operations	2
	Condensed Consolidated Statements of Comprehensive Loss	2
	Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)	3
	Condensed Consolidated Statements of Cash Flows	5
	Notes to Unaudited Condensed Consolidated Financial Statements	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	29
Item 4.	Controls and Procedures	29
PART II.	OTHER INFORMATION	30
Item 1.	Legal Proceedings	30
Item 1A.	Risk Factors	30
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	72
Item 3.	Defaults Upon Senior Securities	72
Item 4.	Mine Safety Disclosures	72
Item 5.	Other Information	72
Item 6.	Exhibits	73
Signatures		74

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

KYMERA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except for share and per share amounts)

(Unaudited)

	March 31, 2021			December 31, 2020
Assets
Current assets:
Cash and cash equivalents	$	53,098		$	31,004
Marketable securities (Note 4)		280,439			265,198
Accounts receivable—due from related parties		856			577
Contract assets—due from related parties		878			856
Prepaid expenses and other current assets		5,520			4,704
Total current assets	$	340,791		$	302,339
Marketable securities, non-current (Note 4)		101,639			162,531
Property and equipment, net (Note 6)		10,752			10,841
Right-of-use assets, operating leases		9,750			9,845
Other non-current assets		30			30
Restricted cash		1,590			1,589
Total assets	$	464,552		$	487,175
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	8,348		$	4,368
Accrued expenses (Note 8)		10,572			10,330
Deferred revenue		87,912			92,552
Operating lease liabilities		2,408			2,572
Finance lease liabilities		640			689
Other current liabilities		257			106
Total current liabilities	$	110,137		$	110,617
Non-current liabilities
Deferred revenue, net of current portion		64,654			77,838
Operating lease liabilities, net of current portion		13,924			14,128
Finance lease liabilities, net of current portion		498			604
Other non-current liabilities		92			100
Total liabilities	$	189,305		$	203,287
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 0 shares issued or outstanding as of March 31, 2021 and December 31, 2020		—			—
Common stock, $0.0001 par value; 150,000,000 shares authorized at March 31, 2021 and December 31, 2020, 44,971,052 and 44,592,288 shares issued at March 31, 2021 and December 31, 2020, respectively; 44,879,376 and 44,482,186 shares outstanding at March 31, 2021 and December 31, 2020, respectively		4			4
Additional paid-in capital		417,096			412,777
Accumulated deficit		(141,840	)		(128,765	)
Accumulated other comprehensive loss		(13	)		(128	)
Total stockholders’ equity		275,247			283,888
Total liabilities and stockholders’ equity	$	464,552		$	487,175

The accompanying notes are an integral part of these condensed consolidated financial statements.

KYMERA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

Three Months Ended March 31, 2021 and 2020

(In thousands, except for share and per share amounts)

(Unaudited)

	Three Months Ended March 31,
	2021			2020
Collaboration Revenue—from related parties	$	18,702		$	3,428
Operating expenses:
Research and development	$	25,962		$	12,116
General and administrative		5,909			2,559
Total operating expenses		31,871			14,675
Loss from operations		(13,169	)		(11,247	)
Other income (expense):
Interest Income		118			349
Interest Expense		(24	)		(34	)
Total other income:		94			315
Net loss	$	(13,075	)	$	(10,932	)
Other comprehensive loss:
Unrealized gain on marketable securities		115			214
Total comprehensive loss	$	(12,960	)	$	(10,718	)
Reconciliation of net loss to net loss attributable to common stockholders:
Net Loss	$	(13,075	)	$	(10,932	)
Deemed dividend from exchange of convertible preferred stock		—			(9,050	)
Net loss attributable to common stockholders	$	(13,075	)	$	(19,982	)
Net loss per share attributable to common stockholders, basic and diluted	$	(0.29	)	$	(10.23	)
Weighted average common stock outstanding, basic and diluted		44,649,572			1,952,667

The accompanying notes are an integral part of these condensed consolidated financial statements.

KYMERA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)

For the three months ended March 31, 2021

(In thousands, except for share amounts)

(Unaudited)

	Common Stock				Additional Paid in		Accumulated			Accumulated Other Comprehensive			'Total Stockholders’
	Shares		Value		Capital		Deficit			Loss			Equity
Balance at December 31, 2020		44,482,186	$	4		412,777	$	(128,765	)	$	(128	)	$	283,888
Exercise of stock options		378,762		—		1,147		—			—			1,147
Vesting restricted stock		18,428		—		—		—			—			—
Stock-based compensation expense		—		—		3,172		—			—			3,172
Unrealized gain on marketable securities		—		—		—		—			115			115
Net Loss		—		—		—		(13,075	)		—			(13,075	)
Balance at March 31, 2021		44,879,376	$	4	$	417,096	$	(141,840	)	$	(13	)	$	275,247

KYMERA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) (continued)

For the three months ended March 31, 2020

(In thousands, except for share amounts)

(Unaudited)

	Series Seed Convertible Preferred Stock				Series A Convertible Preferred Stock						Series B Convertible Preferred Stock				Series B-1 Convertible Preferred Stock				Series C Convertible Preferred Stock				Common Stock				Additional Paid in			Accumulated			Accumulated Other Comprehensive		Total Stockholders' Equity
	Shares		Value		Shares			Value			Shares		Value		Shares		Value		Shares		Value		Shares		Value		Capital			Deficit			Income		(Deficit)
Balance at December 31, 2019		3,000,000	$	5,900		14,720,126		$	29,237			14,827,580	$	59,918		3,059,695	$	14,025		—	$	—		1,929,516	$	—		2,044		$	(76,456	)	$	6	$	(74,406	)
Vesting of Series A Preferred Stock in connection with collaboration arrangement (Note 5)		—		—		55,394			111			—		—		—		—		—		—		—		—		—			—			—		—
Issuance of Series B Preferred Stock, net of issuance costs of $0		—		—		—			—			1,182,265		4,800		—		—		—		—				—		—			—			—		—
Issuance of Series C Preferred Stock, net of issuance costs of $320		—		—		—			—			—		—		—		—		13,539,141		88,180		—		—		—			—			—		—
Exchange of Series A Convertible Preferred Stock for Series C Preferred Convertible Preferred Stock		—		—		(1,988,802	)		(3,950	)		—		—		—		—		1,988,802		13,000		—		—		(2,333	)		(6,717	)		—		(9,050	)
Vesting restricted stock		—		—		—			—			—		—		—		—		—		—		46,297		—		—			—			—		—
Stock-based compensation expense		—		—		—			—			—		—		—		—		—		—		—		—		371			—			—		371
Unrealized gain on marketable securities		—		—		—			—			—		—		—		—		—		—		—		—		—			—			214		214
Net Loss		—		—		—			—			—		—		—		—		—		—		—		—		—			(10,932	)		—		(10,932	)
Balance at March 31, 2020		3,000,000	$	5,900		12,786,718		$	25,398			16,009,845	$	64,718		3,059,695	$	14,025		15,527,943	$	101,180		1,975,813	$	—	$	82		$	(94,105	)	$	220	$	(93,803	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

KYMERA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the three months ended March 31, 2021 and 2020

(In thousands)

(Unaudited)

	Three Months Ended March 31,
	2021			2020
Operating activities
Net loss	$	(13,075	)	$	(10,932	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense		3,172			371
Depreciation and amortization		485			387
Premiums and discounts on available-for-sale marketable securities		1,279			—
Non-cash research and development expense		—			111
Changes in operating assets and liabilities:
Prepaid expenses and other assets		(816	)		(1,477	)
Receivables—due from related parties		(279	)		—
Contract asset—due from related parties		(22	)		—
Accounts payable		4,150			(161	)
Accrued expenses and other current liabilities		235			690
Deferred revenue		(17,822	)		(3,428	)
Operating lease right-of-use assets		95			4,295
Operating lease liabilities		(368	)		(1,913	)
Other liabilities		143			—
Net cash used in operating activities	$	(22,823	)	$	(12,057	)
Investing activities
Purchase of property and equipment, net		(164	)		(1,395	)
Purchases of investments		(16,013	)		(36,008	)
Maturities of investments		60,500			—
Net cash provided by (used in) investing activities	$	44,323		$	(37,403	)
Financing activities
Proceeds from the issuance of Series B Convertible Preferred Stock, net of issuance costs		—			4,800
Proceeds from the issuance of Series C Convertible Preferred Stock, net of issuance costs		—			88,462
Proceeds from stock option exercises		1,147			—
Payments of offering costs in connection with initial public offering		(397	)		—
Payments on finance leases		(155	)		(142	)
Net cash provided by financing activities	$	595		$	93,120
Net increase in cash, cash equivalents and restricted cash		22,095			43,660
Cash, cash equivalents and restricted cash at beginning of period		32,593			77,789
Cash, cash equivalents and restricted cash at end of period	$	54,688		$	121,449
Supplemental disclosure of cash flow activities
Cash paid for interest	$	24		$	34
Supplemental disclosure of noncash investing and financing activities
Offering costs included in accrued liabilities	$	—		$	281
Property and equipment purchases included in accounts payable and accrued expenses	$	259		$	1,714

The following table provides a reconciliation of the cash, cash equivalents, and restricted cash balances as of each of the periods shown above:

	March 31,
	2021		2020
Cash and cash equivalents	$	53,098	$	121,250
Restricted cash		1,590		199
Total cash, cash equivalents, and restricted cash	$	54,688	$	121,449

The accompanying notes are an integral part of these condensed consolidated financial statements.

KYMERA THERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Organization and Nature of Business

Kymera Therapeutics, Inc., together with its subsidiary Kymera Securities Corporation, is referred to on a consolidated basis as the “Company”. The Company is a biopharmaceutical company focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural cellular process, a method known as targeted protein degradation. The Company has devoted its efforts principally to research and development since formation. The Company has not yet completed product development, filed for or obtained regulatory approvals for any products, nor verified the market acceptance and demand for such products. As a result, the Company is subject to a number of risks common to emerging companies in the biotech industry. Principal among these risks are the uncertainties of the product discovery and development process, dependence on key individuals, development of the same or similar technological innovations by the Company’s competitors, protection of proprietary technology, compliance with government regulations and approval requirements, the Company’s ability to access capital and uncertainty of market acceptance of products.

The Company has historical net losses and anticipates that it will continue to incur losses for the foreseeable future and had an accumulated deficit of $141.8 million as of March 31, 2021. The Company has funded these losses principally through issuance of common stock, including its initial public offering (“IPO”), which was completed in August 2020, preferred stock, convertible notes and from cash proceeds received in connection with the Company’s collaboration agreements with Vertex Pharmaceuticals Incorporated (“Vertex”) and Genzyme Corporation (“Sanofi”) (see Note 5). The Company expects to continue to incur operating losses and negative cash flows until such time as it generates a level of revenue that is sufficient to support its cost structure.

As of March 31, 2021, the Company had cash, cash equivalents and marketable securities of $435.2 million. The Company believes these cash, cash equivalents and marketable securities will be sufficient to fund its operations and capital expenditure requirements through at least twelve months from the issuance of these condensed consolidated financial statements.

The Company expects to finance the future research and development costs of its product portfolio with its existing cash, cash equivalents and marketable securities, or through strategic financing opportunities that could include, but are not limited to future offerings of its equity, collaboration agreements, or the incurrence of debt. However, there is no guarantee that any of these strategic or financing opportunities will be executed or realized on favorable terms, if at all, and some could be dilutive to existing stockholders. If the Company fails to obtain additional future capital, it may be unable to complete its planned preclinical studies and clinical trials.

Reverse Stock Split

On August 20, 2020, the Board approved a 1-for-1.5949 reverse stock split of the Company’s issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each of the Company’s outstanding series of preferred stock. All share and per share amounts in the accompanying condensed consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital.

Initial Public Offering

On August 20, 2020, the Company’s registration statement on Form S-1 relating to its initial public offering of its common stock was declared effective by the Securities and Exchange Commission (“SEC”). In the IPO, which closed on August 25, 2020, the Company issued and sold 9,987,520 shares of common stock, including full exercise of the underwriters’ over-allotment option to purchase an additional 1,302,720 shares, at a public offering price of $20.00 per share and the aggregate gross proceeds before deducting underwriting discounts and commissions, and other estimated offering expenses payable by the Company, were approximately $199.8 million. Concurrent with the IPO, the Company issued and sold 676,354 shares of common stock at $20.00 per share in a private placement to Vertex and the aggregate proceeds were $13.5 million.

2. Summary of Significant Accounting Policies

The accompanying consolidated financial statements reflect the application of certain significant accounting policies as described in this note, and elsewhere in the accompanying condensed consolidated financial statements and notes.

KYMERA THERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary Kymera Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.

Basis of Presentation

The unaudited interim condensed consolidated financial statements of the Company included herein have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) as found in the Accounting Standards Codification (“ASC”), Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”) and the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 11, 2021.

The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2020, and, in the opinion of management, reflect all adjustments necessary, all of which were normal and recurring, for the fair statement of the Company’s financial position as of March 31, 2021, and the results of operations and cash flows for the three months ended March 31, 2021 and 2020. The results for the three months ended March 31, 2021 are not necessarily indicative of the results for the year ended December 31, 2021 or for any future period.

Significant Accounting Policies

The significant accounting policies used in preparation of these condensed consolidated financial statements for the three months ended March 31, 2021 are consistent with those discussed in Note 2 to the consolidated financial statements in the 2020 Annual Report on Form 10-K.

Recent Accounting Pronouncements

Recently Adopted Accounting Standards

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The new standard was effective beginning January 1, 2021. The Company adopted this standard as of January 1, 2021 and it did not have a material impact on its financial position or results of operation.

Recently Issued Accounting Standards Not Yet Adopted

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements. The new standard requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. As an emerging growth company, the Company expects to delay adoption until January 1, 2023 and is evaluating the impact that the adoption of ASU 2016-13 will have on its condensed consolidated financial statements.

KYMERA THERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

3. Fair Value Measurements

The following table presents information about the Company’s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of March 31, 2021 and December 31, 2020 (in thousands):

	Fair Value Measurements at March 31, 2021:
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents
Money market fund	$	23,321	$	—	$	—	$	23,321
Marketable securities, current
US treasuries		201,758		—		—		201,758
Corporate bonds		—		78,681		—		78,681
Marketable securities, non-current
US treasuries		86,799		—		—		86,799
Corporate bonds		—		14,840		—		14,840
Restricted cash		1,590		—		—		1,590
Total	$	313,468	$	93,521	$	—	$	406,989

	Fair Value Measurements at December 31, 2020:
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents
Money market fund	$	19,943	$	—	$	—	$	19,943
Corporate bonds		—		10,499		—		10,499
Marketable securities, current
US treasuries		192,275		—		—		192,275
Corporate bonds		—		72,923		—		72,923
Marketable securities, non-current
US treasuries		132,589		—		—		132,589
Corporate bonds		—		29,942		—		29,942
Restricted cash		1,589		—		—		1,589
Total	$	346,396	$	113,364	$	—	$	459,760

During the three months ended March 31, 2021 and the year ended December 31, 2020, there were no transfers between Level 1, Level 2 and Level 3.

4. Marketable Securities

The following table summarizes the available-for-sale debt securities held at March 31, 2021 and December 31, 2020 and (in thousands):

Description	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
March 31, 2021
U.S. treasury securities	$	288,541	$	16	$	—	$	288,557
Corporate securities		93,557